Immunitybio (IBRX) closed at $6.02 on November 13, 2026, down 0.8% from the previous close, on volume of 12,273,468 shares (30-day average 14,253,843).
Data as of November 13, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 12, 2026 | Call with Delta Hedge | 15-Jan-27 11 C +119,000 Stock | 7,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Business Wire (Wed, 11-Nov 8:30 AM ET)
ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
Business Wire (Tue, 10-Nov 9:31 PM ET)
ImmunityBio (IBRX) Gets a Buy from BTIG
TipRanks (Tue, 10-Nov 6:16 AM ET)
TipRanks (Mon, 9-Nov 2:20 PM ET)
Market Chameleon (Mon, 9-Nov 4:54 AM ET)
ImmunityBio GAAP EPS of -$0.18 misses by $0.10, revenue of $48.84M misses by $10.39M
Seeking Alpha News (Mon, 9-Nov 7:39 AM ET)
Business Wire (Mon, 9-Nov 7:30 AM ET)
Business Wire (Mon, 9-Nov 7:00 AM ET)
ImmunityBio Reports Positive ANKTIVA Bladder Cancer Trial Results
TipRanks (Mon, 9-Nov 6:59 AM ET)
Business Wire (Mon, 9-Nov 6:30 AM ET)
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Immunitybio trades on the NASDAQ stock market under the symbol IBRX.
As of November 13, 2026, IBRX stock price declined to $6.02 with 12,273,468 million shares trading.
IBRX has a beta of 1.52, meaning it tends to be more sensitive to market movements. IBRX has a correlation of 0.03 to the broad based SPY ETF.
IBRX has a market cap of $6.40 billion. This is considered a Mid Cap stock.
Last quarter Immunitybio reported $49 million in Revenue and -$.09 earnings per share. This fell short of revenue expectation by $-11 million and missed earnings estimates by -$.03.
In the last 3 years, IBRX traded as high as $12.43 and as low as $1.83.
The top ETF exchange traded funds that IBRX belongs to (by Net Assets): VTI, VB, XBI, IWM, VBK.
IBRX has outperformed the market in the last year with a return of +192.2%, while the SPY ETF gained +11.5%. However, in the most recent history, IBRX shares have underperformed the stock market with its stock returning -22.2% in the last 3 month period and -31.1% for the last 2 week period, while SPY has returned -2.1% and -1.9%, respectively.
IBRX support price is $5.72 and resistance is $6.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBRX shares will trade within this expected range on the day.
